CA3095893A1 - Use of cladribine for treating autoimmune neuromuscular disease - Google Patents

Use of cladribine for treating autoimmune neuromuscular disease Download PDF

Info

Publication number
CA3095893A1
CA3095893A1 CA3095893A CA3095893A CA3095893A1 CA 3095893 A1 CA3095893 A1 CA 3095893A1 CA 3095893 A CA3095893 A CA 3095893A CA 3095893 A CA3095893 A CA 3095893A CA 3095893 A1 CA3095893 A1 CA 3095893A1
Authority
CA
Canada
Prior art keywords
cladribine
composition
treatment
dose
myasthenia gravis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095893A
Other languages
English (en)
French (fr)
Inventor
Konrad REJDAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chord Therapeutics SA
Original Assignee
Chord Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics SA filed Critical Chord Therapeutics SA
Publication of CA3095893A1 publication Critical patent/CA3095893A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CA3095893A 2017-07-21 2018-06-28 Use of cladribine for treating autoimmune neuromuscular disease Pending CA3095893A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1711800.1 2017-07-21
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE

Publications (1)

Publication Number Publication Date
CA3095893A1 true CA3095893A1 (en) 2019-01-24

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095893A Pending CA3095893A1 (en) 2017-07-21 2018-06-28 Use of cladribine for treating autoimmune neuromuscular disease

Country Status (16)

Country Link
US (2) US12171775B2 (OSRAM)
EP (2) EP3654989B1 (OSRAM)
JP (1) JP7186214B2 (OSRAM)
CA (1) CA3095893A1 (OSRAM)
DK (1) DK3654989T3 (OSRAM)
ES (1) ES2974423T3 (OSRAM)
FI (1) FI3654989T3 (OSRAM)
GB (1) GB2564717A (OSRAM)
HR (1) HRP20240282T1 (OSRAM)
HU (1) HUE066238T2 (OSRAM)
LT (1) LT3654989T (OSRAM)
PL (1) PL3654989T3 (OSRAM)
PT (1) PT3654989T (OSRAM)
RS (1) RS65246B1 (OSRAM)
SI (1) SI3654989T1 (OSRAM)
WO (1) WO2019016505A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2025125527A1 (en) 2023-12-14 2025-06-19 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
EP1556010A4 (en) * 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
EP1588283A2 (en) * 2002-11-22 2005-10-26 Transclick, Inc. System and method for language translation via remote devices
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
ES3007339T3 (en) 2004-12-22 2025-03-19 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EA020805B1 (ru) * 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза

Also Published As

Publication number Publication date
DK3654989T3 (da) 2024-02-26
LT3654989T (lt) 2024-03-25
WO2019016505A1 (en) 2019-01-24
RS65246B1 (sr) 2024-03-29
GB2564717A (en) 2019-01-23
JP7186214B2 (ja) 2022-12-08
HRP20240282T1 (hr) 2024-05-10
SI3654989T1 (sl) 2024-06-28
US20250302858A1 (en) 2025-10-02
HUE066238T2 (hu) 2024-07-28
GB201711800D0 (en) 2017-09-06
EP4292663A2 (en) 2023-12-20
JP2020527156A (ja) 2020-09-03
PL3654989T3 (pl) 2024-05-20
EP3654989A1 (en) 2020-05-27
US12171775B2 (en) 2024-12-24
FI3654989T3 (fi) 2024-03-21
ES2974423T3 (es) 2024-06-27
EP4292663A3 (en) 2024-03-20
EP3654989B1 (en) 2024-01-03
US20200163986A1 (en) 2020-05-28
PT3654989T (pt) 2024-02-28

Similar Documents

Publication Publication Date Title
US20250302858A1 (en) Use of cladribine for treating autoimmune neuromuscular disease
AU2015212613B2 (en) Use of cladribine for treating neuromyelitis optica
KR20170131543A (ko) 근위축성 측삭 경화증을 치료하기 위한 비오틴
US20230270743A1 (en) Use of btk inhibitors in the treatment of diseases
HK40106667A (en) Use of cladribine for treating autoimmune neuromuscular disease
HK40031112B (en) Use of cladribine for treating autoimmune neuromuscular disease
HK40031112A (en) Use of cladribine for treating autoimmune neuromuscular disease
EP1032402B1 (en) Use of citicoline for the treatment of multiple sclerosis (MS)
RU2837046C1 (ru) Применение ингибиторов btk при лечении заболеваний
US20020198172A1 (en) Method of treating motor neuron diseases and demyelinating diseases with citicoline
GB2601786A (en) Use of cladribine for treating immune brain disease
VERMEULEN¹ et al. A. BRAND2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230424

EEER Examination request

Effective date: 20230424

EEER Examination request

Effective date: 20230424